Additional Paid in Capital of PharmaCyte Biotech, Inc. from 30 Apr 2011 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
PharmaCyte Biotech, Inc. quarterly Additional Paid in Capital in USD history and change rate from 30 Apr 2011 to 31 Oct 2025.
  • PharmaCyte Biotech, Inc. Additional Paid in Capital for the quarter ending 31 Oct 2025 was $180,611,996, a 0.41% decline year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

PharmaCyte Biotech, Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $180,611,996 -$740,846 -0.41% 31 Oct 2025 10-Q 18 Dec 2025 2026 Q2
Q2 2025 $181,550,139 -$1,172,863 -0.64% 31 Jul 2025 10-Q 15 Sep 2025 2026 Q1
Q1 2025 $181,489,647 -$3,844,526 -2.1% 30 Apr 2025 10-Q 18 Dec 2025 2026 Q2
Q4 2024 $181,425,703 -$7,795,713 -4.1% 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $181,352,842 -$12,237,939 -6.3% 31 Oct 2024 10-Q 13 Dec 2024 2025 Q2
Q2 2024 $182,723,002 -$15,915,762 -8% 31 Jul 2024 10-Q 17 Sep 2024 2025 Q1
Q1 2024 $185,334,173 -$16,896,410 -8.4% 30 Apr 2024 10-K 11 Aug 2025 2025 FY
Q4 2023 $189,221,416 -$13,009,167 -6.4% 31 Jan 2024 10-Q 18 Mar 2024 2024 Q3
Q3 2023 $193,590,781 -$8,009,870 -4% 31 Oct 2023 10-Q 15 Dec 2023 2024 Q2
Q2 2023 $198,638,764 -$2,953,758 -1.5% 31 Jul 2023 10-Q 17 Sep 2024 2025 Q1
Q1 2023 $202,230,583 +$648,476 +0.32% 30 Apr 2023 10-K 13 Aug 2024 2024 FY
Q4 2022 $202,230,583 +$657,215 +0.33% 31 Jan 2023 10-Q 16 Mar 2023 2023 Q3
Q3 2022 $201,600,651 +$45,376 +0.02% 31 Oct 2022 10-Q 14 Dec 2022 2022 Q2
Q2 2022 $201,592,522 +$87,423,391 +77% 31 Jul 2022 10-Q 14 Sep 2022 2023 Q1
Q1 2022 $201,582,107 +$87,472,938 +77% 30 Apr 2022 10-K 31 Jul 2023 2023 FY
Q4 2021 $201,573,368 +$87,724,031 +77% 31 Jan 2022 10-Q 15 Mar 2022 2022 Q3
Q3 2021 $201,555,275 +$87,797,859 +77% 31 Oct 2021 10-Q 14 Dec 2021 2022 Q2
Q2 2021 $114,169,131 +$3,350,136 +3% 31 Jul 2021 10-Q 14 Sep 2021 2022 Q1
Q1 2021 $114,109,169 +$5,140,352 +4.7% 30 Apr 2021 10-K 28 Jul 2022 2022 FY
Q4 2020 $113,849,337 +$6,543,604 +6.1% 31 Jan 2021 10-Q 12 Mar 2021 2021 Q3
Q3 2020 $113,757,416 +$7,102,788 +6.7% 31 Oct 2020 10-Q 11 Dec 2020 2021 Q2
Q2 2020 $110,818,995 +$4,759,187 +4.5% 31 Jul 2020 10-Q 11 Sep 2020 2021 Q1
Q1 2020 $108,968,817 +$4,002,659 +3.8% 30 Apr 2020 10-K 10 Aug 2021 2021 FY
Q4 2019 $107,305,733 +$3,151,805 +3% 31 Jan 2020 10-Q 13 Mar 2020 2020 Q3
Q3 2019 $106,654,628 +$3,130,449 +3% 31 Oct 2019 10-Q 23 Dec 2019 2020 Q2
Q2 2019 $106,059,808 +$2,784,122 +2.7% 31 Jul 2019 10-Q 13 Sep 2019 2020 Q1
Q1 2019 $104,966,158 +$3,329,943 +3.3% 30 Apr 2019 10-K 13 Aug 2020 2020 FY
Q4 2018 $104,153,928 +$3,743,960 +3.7% 31 Jan 2019 10-Q 14 Mar 2019 2019 Q3
Q3 2018 $103,524,179 +$3,635,387 +3.6% 31 Oct 2018 10-Q 14 Dec 2018 2019 Q2
Q2 2018 $103,275,686 +$3,889,989 +3.9% 31 Jul 2018 10-Q 12 Sep 2018 2019 Q1
Q1 2018 $101,636,215 +$4,505,936 +4.6% 30 Apr 2018 10-K 13 Aug 2019 2019 FY
Q4 2017 $100,409,968 +$5,482,180 +5.8% 31 Jan 2018 10-Q 19 Mar 2018 2018 Q3
Q3 2017 $99,888,792 +$6,994,494 +7.5% 31 Oct 2017 10-Q 14 Dec 2017 2018 Q2
Q2 2017 $99,385,697 +$6,681,052 +7.2% 31 Jul 2017 10-Q 13 Sep 2017 2017 Q1
Q1 2017 $97,130,279 +$5,994,909 +6.6% 30 Apr 2017 10-K 20 Jul 2018 2018 FY
Q4 2016 $94,927,788 +$4,500,735 +5% 31 Jan 2017 10-Q 13 Mar 2017 2017 Q3
Q3 2016 $92,894,298 +$4,294,647 +4.8% 31 Oct 2016 10-Q 02 Dec 2016 2017 Q2
Q2 2016 $92,704,645 +$4,808,957 +5.5% 31 Jul 2016 10-Q 06 Sep 2016 2017 Q1
Q1 2016 $91,135,370 +$4,805,146 +5.6% 30 Apr 2016 10-K 27 Jul 2017 2017 FY
Q4 2015 $90,427,053 +$7,184,358 +8.6% 31 Jan 2016 10-Q 08 Mar 2016 2016 Q3
Q3 2015 $88,599,651 +$6,680,004 +8.2% 31 Oct 2015 10-Q/A 19 Jan 2016 2016 Q2
Q2 2015 $87,895,688 +$9,854,613 +13% 31 Jul 2015 10-Q/A 19 Jan 2016 2016 Q1
Q1 2015 $86,330,224 +$10,331,636 +14% 30 Apr 2015 10-K 29 Jul 2016 2016 FY
Q4 2014 $83,242,695 +$27,840,628 +50% 31 Jan 2015 10-Q 13 Mar 2015 2015 Q3
Q3 2014 $81,919,647 +$28,104,643 +52% 31 Oct 2014 10-Q 15 Dec 2014 2015 Q2
Q2 2014 $78,041,075 +$30,182,260 +63% 31 Jul 2014 10-Q 15 Sep 2014 2015 Q1
Q1 2014 $75,998,588 +$36,102,148 +90% 30 Apr 2014 10-K/A 19 Jan 2016 2015 FY
Q4 2013 $55,402,067 +$16,358,256 +42% 31 Jan 2014 10-Q 17 Mar 2014 2014 Q3
Q3 2013 $53,815,004 +$15,172,389 +39% 31 Oct 2013 10-Q 16 Dec 2013 2014 Q2
Q2 2013 $47,858,815 +$9,915,228 +26% 31 Jul 2013 10-Q 16 Sep 2013 2014 Q1
Q1 2013 $39,896,440 +$2,369,916 +6.3% 30 Apr 2013 10-K 04 Aug 2014 2014 FY
Q4 2012 $39,043,811 +$3,583,611 +10% 31 Jan 2013 10-Q 26 Mar 2013 2013 Q3
Q3 2012 $38,642,615 +$3,185,405 +9% 31 Oct 2012 10-Q 26 Dec 2012 2013 Q2
Q2 2012 $37,943,587 +$2,540,777 +7.2% 31 Jul 2012 10-Q 19 Sep 2012 2013 Q1
Q1 2012 $37,526,524 +$3,110,869 +9% 30 Apr 2012 10-K 29 Jul 2013 2013 FY
Q4 2011 $35,460,200 31 Jan 2012 10-Q 21 Mar 2012 2012 Q3
Q3 2011 $35,457,210 31 Oct 2011 10-Q 15 Dec 2011 2012 Q2
Q2 2011 $35,402,810 31 Jul 2011 10-Q/A 20 Sep 2011 2012 Q1
Q1 2011 $34,415,655 30 Apr 2011 10-K 14 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.